BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine

This article was originally published here

Close to 8,000 participants are being enrolled by BiondVax for the second cohort for the late-stage trial of M-001 in 85 sites across seven countries in eastern Europe.

The post BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply